Medicines Co. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
15,260.00
32,348.00
352,746.00
258,854.00
708,373.00
123,156
Depreciation, Depletion & Amortization
32,238.00
34,398.00
34,837.00
31,042.00
21,974.00
3,195
Other Funds
7,675.00
8,510.00
157,601.00
97,278.00
10,525.00
98,527
Funds from Operations
81,119.00
94,142.00
133,357.00
282,815.00
324,858.00
218,488
Changes in Working Capital
10,301.00
26,828.00
64,608.00
40,494.00
43,430.00
43,307
Net Operating Cash Flow
91,420.00
67,314.00
197,965.00
323,309.00
368,288.00
261,795
Capital Expenditures
13,574.00
22,289.00
115,172.00
12,176.00
4,525.00
Sale of Fixed Assets & Businesses
-
-
250.00
437,875.00
-
Purchase/Sale of Investments
51,781.00
3,625.00
19,808.00
3,656.00
503.00
Net Investing Cash Flow
504,361.00
84,756.00
123,511.00
422,043.00
5,195.00
Issuance/Reduction of Debt, Net
-
-
387,231.00
134,078.00
55,000.00
Net Financing Cash Flow
271,487.00
8,833.00
324,828.00
70,576.00
16,904.00
Net Change in Cash
142,719.00
5,986.00
2,432.00
168,662.00
390,476.00
Free Cash Flow
77,846.00
60,025.00
200,520.00
325,485.00
372,813.00
Deferred Taxes & Investment Tax Credit
10,272.00
5,565.00
53,292.00
23.00
89,895.00
-
Net Assets from Acquisitions
542,579.00
58,934.00
28,397.00
-
167.00
Other Sources
11.00
92.00
-
-
-
Change in Capital Stock
263,812.00
17,343.00
95,198.00
33,776.00
48,621.00
Exchange Rate Effect
1,265.00
2,623.00
920.00
648.00
89.00

About Medicines

View Profile
Address
8 Sylvan Way
Parsippany New Jersey 07054
United States
Employees -
Website http://www.themedicinescompany.com
Updated 07/08/2019
The Medicines Co. operates as a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A.